LAVA Therapeutics (NASDAQ:LVTX) Cut to “Hold” at Citizens Jmp

Citizens Jmp downgraded shares of LAVA Therapeutics (NASDAQ:LVTX) from a strong-buy rating to a hold rating in a report released on Wednesday,Zacks.com reports.

Separately, JMP Securities reiterated a “market perform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a report on Wednesday. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.67.

LAVA Therapeutics Trading Down 7.5 %

Shares of NASDAQ LVTX opened at $1.11 on Wednesday. The firm has a 50-day simple moving average of $1.69 and a 200-day simple moving average of $1.83. LAVA Therapeutics has a 52 week low of $1.08 and a 52 week high of $6.47.

Hedge Funds Weigh In On LAVA Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in shares of LAVA Therapeutics during the 3rd quarter valued at approximately $32,000. XTX Topco Ltd acquired a new stake in LAVA Therapeutics during the second quarter worth $55,000. Finally, Pathway Financial Advisors LLC raised its position in LAVA Therapeutics by 328.6% in the second quarter. Pathway Financial Advisors LLC now owns 60,000 shares of the company’s stock valued at $108,000 after purchasing an additional 46,000 shares during the period.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.